NCT01436955View on ClinicalTrials.gov

A Study of RG1662 in Individuals With Down Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Down Syndrome
Interventions
DRUG

Placebo

multiple oral doses

DRUG

RG1662

Cohorts receiving multiple oral doses

Trial Locations (9)

21287

Baltimore

27710

Durham

30033

Decatur

60612

Chicago

72204

Little Rock

80045

Aurora

85013

Phoenix

92037

La Jolla

NW10 7EW

London

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01436955 - A Study of RG1662 in Individuals With Down Syndrome | Biotech Hunter | Biotech Hunter